Purpose Patients with follicular lymphoma (FL) registered in the F2-study and initially
managed without treatment were analyzed to describe the presentation and outcome of a …

Watch and wait (WAW) is a common approach for asymptomatic, advanced stage follicular
lymphoma (FL), but single‐agent rituximab is an alternative for these patients. In this …

Purpose In low–tumor burden follicular lymphoma (FL), maintenance rituximab (MR) has
been shown to improve progression-free survival when compared with observation. It is not …

To examine the effectiveness of an initial management strategy of watchful waiting for
follicular lymphoma (FL) in clinical practice, we compared outcomes for patients diagnosed …

PURPOSE Rituximab improves progression-free survival (PFS) and time to next treatment
(TTNT) when compared with the watch and wait strategy for patients with low–tumor burden …

Purpose Twenty percent of patients with follicular lymphoma (FL) experience progression of
disease (POD) within 2 years of initial chemoimmunotherapy. We analyzed data from the …

Background Patients with advanced-stage, low-tumour-burden follicular lymphoma have
conventionally undergone watchful waiting until disease progression. We assessed whether …

Abstract As previously reported (Colombat, Blood 2001; 97: 101), rituximab (4 weekly doses
of 375mg/m²) can lead to high response rates (RR) and prolonged remissions with minimal …

E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …

Purpose First-line treatment for patients with newly diagnosed follicular lymphoma (FL) still
remains debated, even in the rituximab-based combination therapy era. Few studies have …